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Introduction
In 2013, the Centers for Disease Control (CDC) issued 
antimicrobial resistance guidance ranking carbapenem-
resistant Enterobacteriaceae (CRE), Neisseria gonorrhea, 
and Clostridium difficile as the three most urgent resistance 
threats in the United States [1]. CRE are defined as pathogens 
testing resistant to the following carbapenem antimicrobials 
(imipenem, meropenem, doripenem, or ertapenem) or are 
documented to produce a carbapenemase [2]. In the 2013 
CDC report, an estimated 9,300 inpatient cases were predicted 
annually, and as of December 2017, CRE isolates have now 
been reported in all 50 states [3]. Enterobacteriaceae cause 
roughly 27.2% of healthcare-associated infections (HAIs) in 
acute care settings, with Klebsiella pneumoniae and E. coli 
as the predominant species [4]. Carbapenems are useful last 
line treatment options in multidrug-resistant gram-negative 
infections.  Therefore, CRE are truly a healthcare threat. 
Classification of Carbapenemases
The most common mechanism of carbapenem resistance 
is production of carbapenemases, beta-lactamase enzymes 
conferring one of several mechanisms of carbapenem resistance. 
It is important to note that not all carbapenemases are the same 
and can be classified using either molecular structure (Ambler 
classification) or functional activity (Bush-Jacoby-Medeiros 
classification) [5]. Ambler classes A, B, and D comprise the 
majority of carbapenemases and hydrolyze beta-lactams using 
either a serine or zinc complex that cleaves the beta-lactam 
ring and inactivates the antimicrobial. Among multidrug-
resistant gram-negative bacteria species, Enterobacteriaceae, 
Pseudomonas aeruginosa, and Acinetobacter baumanii are all 
carbapenemase-producing organisms (CPOs). 
In the United States, Class A enzymes including the Klebsiella 
pneumoniae carbapenemase (KPC) are widespread and 
now considered endemic.  KPCs have been documented 
in several Enterobacteriaceae species including Klebsiella 
pneumoniae, E. coli, Citrobacter sp., Enterobacter sp., and 
Serratia marcescens [6]. Using isolates from 2011 – 2015, a 
96% prevalence of the KPC enzyme among all carbapenemases 
in the United States was reported, and the KPC enzyme was 
most commonly acquired by Klebsiella pneumoniae [7]. 
Luckily, several new combination beta-lactams utilizing novel 
beta-lactamase inhibitors have been FDA approved in the 
United States to combat Class A carbapenemases, notably 
ceftazidime-avibactam and meropenem-vaborbactam. 
Class B enzymes, or metallo-beta-lactamases (MBLs), are 
more globally distributed outside of the Unites States. 
They are characterized by the New Delhi metallo-beta-
lactamase (NDM) endemic to India, Verona integrin-
encoded metallo-beta-lactamase (VIM) found in Europe, 
and imipenemase metallo-beta-lactamase (IMP) in Asia 
and Australia [8]. These carbapenemases are very difficult 
to treat, as antimicrobial options are limited.  To date 
in the United States, only older antimicrobials such as 
polymyxins, aminoglycosides, or glycylcyclines are available. 
As noted above, Class C enzymes, commonly known as 
cephalosporinases, do not confer carbapenem resistance are not 
discussed in this article.  Lastly, Class D enzymes are caused by 
a variety of oxacillinase beta-lactamases (OXA) and are endemic 
in northern Africa, eastern Europe, and India.  An example is 
the oxacillinase (OXA) enzyme subtype.
CRE Laboratory Detection
Accurate laboratory detection of carbapenemases is essential 
to optimize patient care and facilitate timely infection control 
prevention measures.  In the United States, CRE isolates are 
reportable to state health departments, with further tracking 
by the CDC.  Laboratories have faced challenges with accurately 
identifying isolates. Some isolates tested susceptible to 
carbapenems, however, carbapenem MICs were elevated.  In 
addition, some automated susceptibility testing systems failed to 
detect low-level carbapenem resistance.  In 2010, the Clinical and 
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Laboratory Standards Institute (CLSI) lowered the carbapenem 
breakpoints in an effort to facilitate detection and reporting 
of carbapenem-resistant isolates.  The US Food and Drug 
Administration (FDA) shortly followed by updating medication 
package inserts. With the current guidance, supplemental 
testing outside of automated susceptibility testing instruments 
(AST) is no longer recommended.  Institutions using older 
ASTs should update their equipment according to the newer 
breakpoints.  Humphries R, et al. validated the accuracy of 
newer breakpoints to detect carbapenem-resistant isolates 
by comparing to polymerase chain reaction (PCR) assay for a 
variety of carbapenemase genes.  Results indicated that few 
PCR-proven carbapenemase-producing isolates were reported 
as susceptible; <1% for ertapenem and imipenem, whereas 
2.9% for meropenem [6]. Aside from AST, inaccuracies with the 
modified Hodge test have led to development of more reliable 
supplementary testing methodologies including the Carba-
NP and carbapenem inactivation method.  CLSI updates their 
testing recommendations annually, so please refer to that 
reference for the most up-to-date information.  
CRE Infections
The 2013 CDC Urgent Threat Report identified the following 
patients at high risk for antibiotic resistant infections; 
immunocompromised patients (cancer chemotherapy, organ 
and bone marrow transplant, rheumatoid arthritis), dialysis 
patients, and complex surgical patients [1]. Closer examination 
of CRE infection literature confirms that dialysis and renal 
replacement therapy are indeed identifiable risk factors. 
Other risk factors include intensive care unit (ICU) admission, 
receipt of antimicrobials in the previous 90 days, cumulative 
antimicrobial exposures in the current admission, healthcare 
facility exposure/transfer, and poor functional status [9,10,11].
The impact of CRE infection on clinical outcomes is daunting. 
Using data from the Consortium on Resistance Against 
Carbapenems in Klebsiella and other Enterobacteriaceae 
(CRACKLE) study, a prospective, multicenter, observational 
cohort, Hauck et al. evaluated clinical outcomes in 260 CRE 
Klebsiella pneumoniae patients with bloodstream infection 
(BSI), pneumonia, and urinary tract infection (UTI) compared 
to those with CRE colonization and no active infection.   A two-
fold increase in excess mortality was observed in patients with 
BSI and pneumonia (27% versus 12%), but not with UTI [12]. 
Other studies have described CRE BSI mortality rates between 
40-70% [9]. A recent BSI study demonstrated that when 
carbapenem resistance was caused by a carbapenemase enzyme 
versus another resistance mechanism (ie, outer membrane 
porin changes), outcomes were worse.  Authors suggest that 
carbapenemase-mediated resistance may be more virulent, 
although specific virulence factors were not elucidated [13]. 
An international, multicenter, retrospective study including 
256 cases of CRE infection described overall 28-day mortality 
rates of 28.1%. A disparity was observed among severities of 
infection; 17.3% mortality with cUTI and pyelonephritis, but 
up to 44% with severe infections particularly with the following 
comorbidities were present; renal failure, sepsis, and immune-
deficiency [14]. The mortality data discussed in this section was 
analyzed prior to the clinical use of newer agents that will be 
discussed below.
Also using data from CRACKLE, Eilertson et al. compared 
clinical outcomes in CRE-infected patients with healthy renal 
function versus those with renal replacement therapy (RRT). 
RRT patients are known from previous studies to have increased 
risk of mortality and infectious complications caused by 
multidrug-resistant pathogens including sepsis and pneumonia. 
In this study, those infected with CRE had worse outcomes 
than non-CRE RRT patients; 31% 28-day in hospital mortality 
[15]. Satlin et al. describe mortality rates of 40% in solid organ 
transplant and 65% of hematologic malignancy patients. 
Due to the potential for devastating patient outcomes in an 
immunocompromised population, the authors emphasize the 
importance of active surveillance and antimicrobial stewardship 
to aid in prevention of infection in these patients [16].
CRE Outbreaks
CRE isolates are a major focus of infection control programs 
since carbapenemases, especially KPCs, can be shared via 
mobile plasmids resulting in healthcare-associated institution 
outbreaks.  It is important to implement effective infection 
control measures including contact isolation precautions, hand 
hygiene, surveillance, patient isolation, and environmental 
cleaning in patients with active or prior CRE infections [17]. In 
2011, Detroit Medical Center reported an outbreak of colistin-
resistant NDM-producing Klebsiella pneumoniae involving 
three institutions caused by patient-to-patient transmission 
[18]. A rural Kentucky hospital reported a CRE outbreak 
occurring in 2016 from the emergency room to a specific hospital 
ward.  During a 4-month period, the facility detected 23 CRE 
cases including both KPC and NDM1 carbapenemases.  Through 
a CDC investigation, two observations were made; first, CRE 
isolates can be spread from urban to rural healthcare settings, 
and second, environmental cleaning carts (or any equipment 
moving throughout the facility) can be modes of transmission 
[19]. Outbreaks have been reported throughout the United 
States involving duodenoscopes or ventilators, invasive devices 
such as urinary catheters, hospital room sinks and bedrails, and 
have been spread across healthcare networks involving acute 
care and long-term acute care (LTAC) facilities [20,21].
CRE Treatment Options
CRE isolates are resistant to almost all beta-lactams leaving 
few, and unfortunately older, drug classes with adequate 
activity.  Specifically, these older treatment options include 
aminoglycosides, polymyxins, a glycylcycline, and fosfomycin 
[22]. Table 1 provides dosing regimens and compares 
advantages and disadvantages of these older agents.  It is 
important to note that polymyxin B and colistin (polymyxin 
E) are not identical in their adverse effect or pharmacokinetic 
profiles.  At the time of publication, CLSI does not provide 
interpretive criteria for polymyxins for Enterobacteriaceae, and 
susceptibility testing for Pseudomonas aeruginosa is no longer 
recommended via Etest gradient diffusion or disk diffusion 
due to unreliable results [23]. Colistin methanesulfonate 
(CMS), a prodrug, requires renal elimination then hydrolysis 
for conversion to its active metabolite, colistin.  This step is 
greatly impacted by renal dysfunction leading to high inter- and 
intra-patient variability in the serum concentrations of active 
drug.   In patients with healthy renal function, 80% of CMS is 
eliminated in the urine before metabolism to the active drug 
even occurs, leaving subtherapeutic serum concentrations for 
non-urinary tract infections [24]. Polymyxin B is not impacted 
by this metabolic process and should be considered as the 
polymyxin of choice for systemic treatment of non-urinary 
tract infections.  With regards to adverse effects, polymyxin 
B has also been shown to be less nephrotoxic to renal tubular 
cells [25]. A meta-analysis comparing differences in mortality 
and adverse effects between the two agents found no difference 
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3Table 1 Older Agents for Treatment of CRE
Antimicrobial Recommended Dosing 
for CRE Infections 
Advantages Disadvantages 
Colistin 1,2,3,4,5  
(Polymyxin E) 
¥ Dosed in milligrams 
versus international 
units (14) at CMS 
¥ Weight-based and fixed 
dose regimens have 
been evaluated (see 
reference 5) 
¥ Loading dose is 
recommended 
¥ Requires dosage 
adjustment in renal 
impairment 
¥ Extensive evidence 
for use in cUTI 
¥ Adjunctive 
inhalation route for 
HAP/VAP 
¥ Pharmacokinetic disadvantages compared to 
polymyxin B. Should only be used for 
urinary tract infections 
¥ Combination therapy required 
¥ Optimal dosing uncertain 
¥ Emergence of resistance 
¥ Nephrotoxicity 
¥ Lack of activity against Proteus sp. and 
Serratia marcescens 
¥ Unreliable antimicrobial susceptibility 
testing 
Polymyxin B 2,5 ¥ Weight-based dose 
regimens (mg/kg and 
14/kg)  
(see reference 5) 
¥ Loading dose is 
reccommended 
¥ Extensive evidence 
for use in BSI, PNA, 
and sepsis 
¥ Adjunctive 
inhalation route for 
HAP/VAP 
¥ Combination therapy required 
¥ Optimal dosing uncertain 
¥ Avoid use in urinary tract infections 
¥ Emergence of resistance 
¥ Nephrotoxicity 
¥ Lack of activity against Proteus sp. and 
Serratia marcescens 
¥ Unreliable antimicrobial susceptibility 
testing 
Tigecycline 6 100-200 mg IV x1, then 
either 50 mg IV q12h or 100 
mg IV q24h 
¥ Stable against many 
beta-lactamases 
¥ Bacteriostatic activity 
¥ Black Box Warning for all-cause mortality 
(2013) 
¥ Increasing antimicrobial resistance 
¥ Dose-dependent adverse effects (mostly GI-
related) 
¥ Pharmacokinetic limitations (inadequate 
serum concentrations for treatment of BSI) 




3 g oral single-dose versus 
every 48h x3 doses (UTI 
only) 
¥ Excellent urine 
penetration 




¥ Only available orally for treatment of lower 
UTI in the United States 




G: 7 mg/kg/day IV 
A: 15 mg/kg/day IV 
¥ Bactericidal activity 
¥ Most efficacious 
option for cUTI 
¥ Extended interval 
dosing  
¥ Inhalation route for 
HAP/VAP 
¥ Nephrotoxicity, ototoxicity 
¥ Combination therapy required, unless cUTI 
Definitions: BSI: bloodstream infections, cUTI: complicated urinary tract infections, PNA: pneumonia, HAP: hospital-acquired pneumonia,  
VAP: ventilator-associated pneumonia 
1. Dosed using colistimethate sodium, the prodrug and manufactured formulation in the United States. 
2. Polymyxins have identical antimicrobial spectrum against gram-negative pathogens, including lack activity against Proteus sp. and Serratia marcescens.  
3. IDSA HAP/VAP Guidelines support use, but European HAP/VAP guidelines disagree citing inadequate pulmonary delivery via nebulization and lack of evidence.  
Inhalation can be used for active infection in combination with a systemic agent, or as prophylaxis in cystic fibrosis patients.  Kidd JM, et al. Novel pharmacotherapy for 
the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria. Exp Opin Pharmacother 2018;19(4):397-408 
4. Liu YY, et al.  Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological 
study. Lancet Infect Dis 2016;16(2):161-68 
5. Tsuji BT, et al. International Consensus Guidelines for the Optional Use of the Polymyxins: Endorsed by ACCP, ESCMID, IDSA, ISAP, SCCM, and SIDP. Pharmacotherapy. 
2019 Jan; 39(1):10-39.  
6. Antimicrobial resistance of tigecycline to Pseudomonas aeruginosa represents a classwide lack in antimicrobial spectrum among all tetracyclines  
7. Karageorgopolous D, et al. Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteremia: report of three cases. J Antimicrob 
Chemother. 2012;67(11):2777-9 
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in clinical outcomes, but an increase in nephrotoxicity with 
colistin [26]. Future studies are needed to determine whether 
pharmacokinetic differences truly translate to undesirable 
patient clinical outcomes.  
Alexander E, et al performed an international, multicenter 
CRE review using isolates from 2013-2014 and found overall 
antimicrobial resistance rates of greater than 80% to penicillins, 
cephalosporins, aztreonam, fluoroquinolones (FQs), and 
trimethoprim/sulfamethoxazole (TMP/SMX).  The same CRE 
isolate review found antimicrobial resistance rates of 80% to 
tobramycin, 57.8% to amikacin, 43.1% to gentamicin, 37% to 
tigecycline, 26.4% to polymyxins [14]. The isolates in this study 
reflect an international summary of antimicrobial resistance 
and may not predict regional antimicrobial resistance trends. 
Antimicrobial stewardship programs (ASPs) have a profound 
effect on local institution resistance patterns by closely 
monitoring antimicrobial utilization.  Luckily, newer beta-
lactam agents and an aminoglycoside have been FDA approved 
in the United States to combat these highly resistant pathogens.
Treatment strategies utilizing these older agents is complex, 
and ongoing research regarding novel combination therapies 
has helped to optimize therapies.  Combinations utilizing 
polymyxins, tigecycline, or aminoglycosides with or without 
a carbapenem have been described with mixed results.  The 
polymyxins, aminoglycosides (except for treatment UTI), and 
intravenous fosfomycin should always be used in combination 
to prevent emergence of antimicrobial resistance.  In a 2014 
review of 20 studies using older agents to treat CRE infections, 
mortality rates were lower when combination therapy was 
utilized compared to monotherapy (27.4% vs. 38.7%; p < 0.001, 
respectively).  In addition, combination regimens containing 
carbapenems resulted in the lowest mortality rates (18.8%) [27].
Other studies have found conflicting evidence regarding 
combination therapies with older agents.  A 2014 meta-analysis 
of 692 patients described mortality rates for tigecycline-colistin 
and carbapenem-colistin regimens of 64% and 67%.  Due to lack 
of statistically significant benefit of combination therapy in all 
infection types, authors concluded that it may only be beneficial 
in severely ill patients with severe infections [28].  Another 
review of 661 KPC infection episodes in Italy illustrated that only 
those patients with high-risk infection (defined as non-UTI) or a 
meropenem MIC ≤8 mg/L. benefited from combination therapy 
[29]. In a recent randomized, controlled trial of 406 patients 
with pneumonia or bacteremia, Paul M et al evaluated colistin 
alone versus colistin plus meropenem for carbapenem-resistant 
gram-negative infections [30]. Although the majority of 
infections in this study were caused by Acinetobacter baumanii 
instead of CRE isolates, combination therapy was not superior 
to monotherapy and resulted in an increase in adverse effects, 
most notably diarrhea.    
Knowing whether an isolate is interpreted as intermediate or 
resistant to carbapenems is clinically relevant.  Use of prolonged 
infusions and combination therapy can be implemented 
to overcome intermediate resistance and improve clinical 
outcomes.  Trained antimicrobial stewardship experts 
(physicians and pharmacists) are valuable resources for 
antimicrobial selection and dosage optimization.  In addition, 
infectious disease consultation is associated with decreased 
30-day readmission, mortality, length of stay, and overall cost, 
particularly in patients with Staphylococcus aureus bacteremia 
and multidrug-resistant gram-negative infections [31,32,33].
Newer Agents with CRE-Activity
Ceftazidime-avibactam (CAZ-AVI) is an intravenous 
cephalosporin/beta-lactamase inhibitor combination. 
Avibactam, a novel non-beta-lactam beta-lactamase inhibitor 
(NB-BLI) diazabicyclooctane (DBO), is currently commercially 
available as a combination agent with ceftazidime, and is also 
being studied in combination with aztreonam and ceftaroline 
[34]. CAZ-AVI inhibits Class A, C, and some D enzymes, but 
is inactive against Class B MBLs.  It is most clinically useful 
for its activity against extended-spectrum beta-lactamases 
(ESBLs) and KPC carbapenemases.  In 2015, CAZ-AVI was FDA 
approved for treatment of complicated urinary tract infections 
including acute pyelonephritis (cUTI/AP) and complicated 
intra-abdominal infections (cIAI) in addition to metronidazole. 
In early 2018, CAZ-AVI also gained FDA approval for hospital-
acquired pneumonia (HAP) and ventilator-associated 
pneumonia (VAP). The pneumonia trial comparator was 
meropenem 1g IV q8h [35]. CAZ-AVI should be administered 
2.5g IV q8h infused over 2 hours, and a renal dosage adjustment 
is required for patients with a creatinine clearance (CrCl) <50 
ml/min.  Reported adverse effects from Phase 3 trials are similar 
to ceftazidime monotherapy.
Although patients infected with CRE-producing strains were 
excluded from the cUTI, cIAI and pneumonia trials due to lack 
of CRE activity with the comparator agents, newer clinical 
experiences describe efficacy and use of combination therapy 
for CRE infections.  Two retrospective studies evaluated 
clinical success and mortality rates in CRE patients treated 
with CAZ-AVI.  In both studies, Klebsiella pneumoniae was 
the predominant strain.  Shields RK, et al. evaluated 30-day 
clinical success and mortality rates in thirty-seven cases.  Fifty 
percent were diagnosed with HAP or VAP, and 70% were treated 
with monotherapy [36]. King et al, evaluated end of treatment 
clinical success and mortality rates in sixty cases [37]. The 
most common infection types were bacteremia, pneumonia, 
and UTI, and 55% were treated with monotherapy.  Between 
the two studies, clinical success rates were similar regardless of 
the timepoint, 59% and 65% respectively.  Mortality rates were 
also similar; in-hospital mortality 32%, and 30- and 90-day 
mortality, 24% and 38%.  CAZ-AVI resistance developed during 
therapy in both studies.  The King study found no statistically 
significant difference in outcomes between monotherapy and 
combination therapy.
Other studies have compared CAZ-AVI to alternative agents 
for treatment of CRE infections.  A comparative study between 
CAZ-AVI-containing regimens and alternative regimens 
(mostly combinations with carbapenems) in patients with 
KPC-Klebsiella pneumoniae bacteremia demonstrated higher 
clinical success rates (85% versus 37-48%, P = 0.04).  90-Day 
mortality rates were lowest among patients receiving CAZ-
AVI regimens.  Patients receiving combination regimens 
containing an aminoglycoside or colistin experienced a higher 
rate of nephrotoxicity [38]. Another comparative study (n = 137 
patients), using data from the CRACKLE database, analyzed 
efficacy, safety, and benefit-risk outcomes between CAZ-AVI- 
and colistin-containing initial treatment regimens.  Patients 
had a greater probability of a better outcome in all categories 
with initial treatment with CAZ-AVI versus colistin.  Fourteen 
(37%) patients were treated with monotherapy in the CAZ-AVI 
arm [39].
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5Table 2 Antimicrobial Pipeline for Treatment of CRE infections
Antimicrobial  Drug Class Indications Notes 
Cefiderocol (CFDC)1,2,3 Siderophore 
cephalosporin 
Phase 3 RCT cUTI/AP 
¥ CFDC 2 g IV every 8 hr vs. 
imipenem/cilastatin 1 g IV every 8 
hr  
¥ DOT 7-14 days 
Phase 3 RCT HABP/VABP 
¥ CFDC 2 g IV every 8 hr vs. 
meropenem 2 g IV every 8h plus 
linezolid 600 mg IV every 12 hr 
¥ DOT 7-14 days 
Phase 3 RCT HABP/VABP, 
BSI/Sepsis, cUTI 
¥ CFDC 2 g IV every 8 hr vs. best 
available therapy for CRE 
DOT 7-14 days 
¥ Active against all 
carbapenemases 
including Class B MBLs 
¥ Adverse effects similar to 
other cephalosporins 







Phase 3 RCT cUTI, cIAI, or 
HABP/VABP 
¥ IMI-REL 500-250 mg IV every 6 hr 
vs. imipenem/cilastatin 500 mg IV 
every 6 hr plus colistin IV every 8-
12 hr 
¥ DOT 5-21 days (cUTI/cIAI) or 7-21 
days (HABP/VABP) 
Phase 3 RCT HABP/VABP 
¥ IMI-REL 500-250 mg IV every 6 hr 
vs. piperacillin/tazobactam 4.5 g IV 
every 6 hr 
¥ DOT 7-14 days 
¥ Active against Class A, C, 
and D carbapenemases 






Phase 3 RCT cIAI, HABP/VABP 
¥ ATM-AVI 6.5/2.1 g loading dose, 
then 6/2 g daily divided every 8 hr 
+/- metronidazole 500 mg IV every 
8 hr vs. meropenem 1-2 g IV every 
8h +/- colistin IV every 8-12 hr 
¥ Active against Class A, C 
and D carbapenemases 
¥ Inactive against Class B 
MBLs 




Phase 2/3 RCT cUTI/AP 
¥ Fosfomycin 6 g IV every 8 hr vs. 
piperacillin/tazobactam 4.5 g IV 
every 6 hr 
¥ DOT 7 days, 14 days if bacteremia 
¥ Active against Class A, C 
and D carbapenemases 
¥ Variable activity against 
Class B MBLs 
¥ Intravenous formulation 
available in many 
countries 
¥ Dose optimization 
studies are ongoing for 
use in the United States 




Definitions: RCT: randomized controlled trial, BSI: bloodstream infections, cUTI: complicated urinary tract infections, AP: acute pyelonephritis, HABP: hospital-acquired bacterial 
pneumonia, VABP: ventilator-associated bacterial pneumonia, NB-BLI DBO: non-beta-lactam beta-lactamase inhibitor diazabicyclooctane, cIAI: complicated intra-abdominal 
infection, DOT: duration of therapy 
1. Ito A, et al.  In Vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria.  Antimicrob Agent Chemother 
2018;62(1):e01454-17 
2. Portsmouth S, et al.  Clinical response of cefiderocol compared with imipenem/cilastatin in the treatment of adults with complicated urinary tract infections with or without 
pyelonephritis or acute uncomplicated pyelonephritis: results from a multicenter, double-blind, randomized study (APEKS-cUTI).  Open Forum Infect Dis 2017;4(Suppl 1):S537  
3. Clinical study of S-649266 for the treatment of nosocomial pneumonia caused by gram-negative pathogens (APEKS-NP) [Internet] Identifier NCT03032380 Bethesda MD: 
National Library of Medicine [cited 2018 May 14] 
4. Zhanel G, et al. Imipenem-relebactam and meropenem-vaborbactam: Two novel carbapenem-beta-lactamase inhibitor combinations.  Drugs 2018 Jan;78(1):65-98 
5. Kidd JM, et al.  Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria.  Expert 
Opinion on Pharmacotherapy 2018;19(4):397-408  
6. A study to determine the efficacy, safety and tolerability of aztreonam-avibactam (ATM/AVI) +/- metronidazole versus meropenem +/- colistin for the treatment of serious 
infections due to gram-negative bacteria. [Internet] Identifier NCT03329092 Bethesda MD: National Library of Medicine [cited 2018 May 14] 
7. Kaye K, et al.  Intravenous fosfomycin (ZTI-01) for the treatment of complicated urinary tract infections including acute pyelonephritis: results from a multicenter, 
randomized, double-blind Phase 2/3 study in hospitalized adults (ZEUS). Open Forum Infect Dis 2017;4(Suppl1):S528. #1845 
8. Karageorgopoulos DE, et al.  Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in gram-negative pathogens.  J Antimicrob 
Chemother 2012;67(2):255-68 
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Meropenem-vaborbactam (MVB) is an intravenous carbapenem/
beta-lactamase inhibitor combination. Vaborbactam is the first 
non-beta-lactam boronic acid inhibitor with activity against 
Class A and C beta-lactamases, and is inactive against Class B 
MBLs. Similar to CAZ-AVI, MVB is also most clinically useful 
for its activity against ESBLs and KPC carbapenemases [40]. 
In 2017, MVB was FDA approved for treatment of cUTI/AP 
(TANGO-1 trial).  The comparator was piperacillin-tazobactam, 
and patients could be switched to oral levofloxacin to complete 
treatment.  Few CRE infections were included in this trial [41]. 
MVB 2g/2g IV should be administered every 8 hours infused 
over 3 hours, and a renal dosage adjustment is required for 
patients with a creatinine clearance (CrCl) <50 ml/min. 
Reported adverse effects from Phase 3 trials are similar to 
meropenem monotherapy. 
The TANGO-2 trial is a Phase 3 study including patients with 
CRE infection (59.7%).  Patients with cUTI/pyelonephritis, 
cIAI, bacteremia, nosocomial pneumonia were included, 
and the comparator was “best available therapy” (BAT), 
meaning one of the older anti-CRE agents discussed above 
as monotherapy or in combination.  Recognizing that CRE 
patients have multiple comorbidities and are different than 
typical study populations for these types of infections, study 
investigators performed a retrospective review of patients with 
CRE infections in order to better define study design enrollment 
criteria [14]. Authors estimate that only 22% of the TANGO-2 
study population would have met enrollment using traditional 
criteria.  As a result of the study, it is unique that the TANGO-2 
study allowed immunocompromised patients, and those with 
severe sepsis and renal insufficiency needing dialysis, although 
these types of patients did not comprise the majority of those 
enrolled.  Enrollment in the BAT arm was discontinued early 
when interim analysis revealed better outcomes in MVB-treated 
patients; in CRE patients, clinical cure 57.1% versus 26.7%. 
Despite promising clinical outcomes, minimum inhibitory 
concentrations (MIC) increased in several MVB-treated isolates 
[42,43].
Plazomicin (PZM) is an intravenous aminoglycoside 
antimicrobial with activity against ESBL- and carbapenemase-
producing aerobic gram negative rods. It is stable against 
aminoglycoside modifying enzymes that inactivate gentamicin, 
tobramycin, and amikacin, and most carbapenemase classes, 
including some activity against Class B MBLs (except NDM) 
[44]. There is limited activity against Stenotrophomonas 
maltophilia, Acinetobacter baumanii, and Pseudomonas 
aeruginosa, and future studies are needed to determine 
clinical utility for these pathogens.   In 2018, PZM gained 
FDA approval for treatment of cUTI/AP (EPIC trial) [45]. The 
comparator was meropenem 1g IV q8h as a 30 minute infusion, 
and a switch to an oral agent was allowed at 4 days.  PZM was 
studied using extended interval dosing, 15 mg/kg IV once daily 
over 30 minutes, and a renal dosage adjustment is required for 
patients with a creatinine clearance (CrCl) <60 ml/min. Forty 
percent of Enterobacteriaceae isolates were an ESBL-producing 
or aminoglycoside non-susceptible strain. Therapeutic drug 
monitoring of a serum trough concentration (goal ≤3 mg/L) is 
recommended 30 minutes prior to the second dose.
With regards to adverse effects, in the EPIC study the 
incidence of nephrotoxicity in the PZM arm, defined as a serum 
creatinine increase of ≥0.5 mg/dL, was 3.6%. Results from 
another Phase 2 study comparing PZM to levofloxacin 750 
daily for cUTI/AP suggest higher nephrotoxicity when 15 mg/
kg was used compared to 10 mg/kg, although the higher dose 
was selected for Phase 3 trials to optimize pharmacokinetic 
and pharmacodynamic targets [46]. A Phase 3, open label, 
Combating Antibiotic-Resistant Enterobacteriaceae (CARE) 
study evaluated plazomicin versus colistin in combination 
with meropenem or tigecycline for serious CRE infections (BSI 
and HABP/VABP).  Results include lower 28-day all-cause 
mortality, higher microbiological response rates, and reduced 
nephrotoxicity.  Authors concluded that plazomicin-based 
combination therapy had a better efficacy and safety profile 
compared to colistin-based combination regimens [47,48]. 
Although classwide warnings for nephrotoxicity, ototoxicity, 
neuromuscular blockage, and fetal harm were included in 
product labeling, the incidence of nephrotoxicity appears to 
be reduced compared to colistin or earlier aminoglycosides, 
especially when therapeutic drug monitoring is utilized.
In summary, for the two newer beta-lactam agents CAZ-AVI 
and MVB, safety and efficacy data appear favorable compared 
to older therapies for CRE infections.  It Is concerning that 
MIC elevations, some conferring resistance to both CAZ-AVI 
and MVB, were observed.  PZM offers a potential expanded 
CRE spectrum of activity and a better safety and efficacy profile 
compared to colistin-based combination regimens.  Future 
studies are needed to optimize protection against antimicrobial 
resistance through combination therapy or optimal dosing.’
Antimicrobial Pipeline
Several agents with novel mechanisms of action are in the 
antimicrobial development pipeline.  Table 2 lists five agents 
with Phase 2 and 3 clinical trial data, and likely review for FDA 
approval in the near future.  Both non-CRE and CRE studies 
were included in the table.
Conclusions
CRE infections are a healthcare and public health threat. 
Mortality rates are high, and agents with better safety and 
efficacy profiles plus expanded carbapenemase activity are 
desperately needed.  When using older agents, combination 
therapy, particularly carbapenem-containing regimens, reduces 
mortality with severe infections, but may not have as much of 
a benefit with UTIs. Three newer agents, CAZ-AVI, MVB and 
PZM, are available and have activity against Class A-producing 
Klebsiella pneumoniae, the predominant CRE pathogen in 
the United States.  In small studies, these agents demonstrate 
promising these clinical outcome and mortality data compared 
to older agents.  However, further studies are needed to 
optimize their use (monotherapy versus combination therapy) 
and prevent emergence of therapy.  Infections caused by MBLs 
remain infrequent in the United States, and treatment options 
against these strains are sparse.  Several antimicrobial agents 
are in the pipeline to address this need.
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